S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
Log in
NASDAQ:ALXN

Alexion Pharmaceuticals Stock Forecast, Price & News

$157.86
+0.12 (+0.08 %)
(As of 01/21/2021 12:00 AM ET)
Add
Compare
Today's Range
$157.78
Now: $157.86
$158.94
50-Day Range
$117.74
MA: $148.17
$158.71
52-Week Range
$72.67
Now: $157.86
$160.03
Volume3.50 million shs
Average Volume3.38 million shs
Market Capitalization$34.55 billion
P/E Ratio36.88
Dividend YieldN/A
Beta1.33
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG and NMOSD; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1810 (Subcutaneous) that is in Phase I clinical trial for renal diseases; and ALXN1720 (Subcutaneous), which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 and ABY-039, which are in Phase I clinical trials for neonatal Fc receptor. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; collaborations with Caelum Biosciences, Inc., Dicerna Pharmaceuticals, Inc. and Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc.; agreement with Stealth BioTherapeutics Corp.; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
Alexion Pharmaceuticals logo

MarketRank

Overall MarketRank

1.77 out of 5 stars

Medical Sector

153rd out of 1,926 stocks

Pharmaceutical Preparations Industry

76th out of 773 stocks

Analyst Opinion: 2.2Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ALXN
CUSIP01535110
Phone475-230-2596
Employees3,082

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.99 billion
Cash Flow$11.79 per share
Book Value$50.91 per share

Profitability

Net Income$2.40 billion

Miscellaneous

Market Cap$34.55 billion
Next Earnings Date2/4/2021 (Estimated)
OptionableOptionable
$157.86
+0.12 (+0.08 %)
(As of 01/21/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ALXN News and Ratings via Email

Sign-up to receive the latest news and ratings for ALXN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Alexion Pharmaceuticals (NASDAQ:ALXN) Frequently Asked Questions

How has Alexion Pharmaceuticals' stock been impacted by Coronavirus?

Alexion Pharmaceuticals' stock was trading at $83.77 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ALXN shares have increased by 88.4% and is now trading at $157.86.
View which stocks have been most impacted by COVID-19
.

Is Alexion Pharmaceuticals a buy right now?

27 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alexion Pharmaceuticals in the last twelve months. There are currently 16 hold ratings, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Alexion Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALXN, but not buy additional shares or sell existing shares.
View analyst ratings for Alexion Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Alexion Pharmaceuticals?

Wall Street analysts have given Alexion Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Alexion Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Alexion Pharmaceuticals' CEO?

1,448 employees have rated Alexion Pharmaceuticals CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Alexion Pharmaceuticals' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Alexion Pharmaceuticals' next earnings date?

Alexion Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for Alexion Pharmaceuticals
.

How were Alexion Pharmaceuticals' earnings last quarter?

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) issued its quarterly earnings results on Tuesday, November, 3rd. The biopharmaceutical company reported $3.24 earnings per share for the quarter, topping the Zacks' consensus estimate of $2.60 by $0.64. The biopharmaceutical company had revenue of $1.59 billion for the quarter, compared to analysts' expectations of $1.43 billion. Alexion Pharmaceuticals had a net margin of 16.32% and a return on equity of 23.16%. The company's revenue for the quarter was up 25.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.79 EPS.
View Alexion Pharmaceuticals' earnings history
.

What guidance has Alexion Pharmaceuticals issued on next quarter's earnings?

Alexion Pharmaceuticals updated its FY 2020 Pre-Market earnings guidance on Tuesday, January, 12th. The company provided EPS guidance of for the period. The company issued revenue guidance of $5.95 billion, compared to the consensus revenue estimate of $5.99 billion.

What price target have analysts set for ALXN?

27 equities research analysts have issued 12-month target prices for Alexion Pharmaceuticals' shares. Their forecasts range from $73.00 to $200.00. On average, they anticipate Alexion Pharmaceuticals' stock price to reach $152.96 in the next year. This suggests that the stock has a possible downside of 3.1%.
View analysts' price targets for Alexion Pharmaceuticals
or view Wall Street analyst' top-rated stocks.

Are investors shorting Alexion Pharmaceuticals?

Alexion Pharmaceuticals saw a decrease in short interest in the month of December. As of December 31st, there was short interest totaling 3,530,000 shares, a decrease of 17.1% from the December 15th total of 4,260,000 shares. Based on an average trading volume of 2,360,000 shares, the days-to-cover ratio is presently 1.5 days. Currently, 1.6% of the shares of the company are sold short.
View Alexion Pharmaceuticals' Short Interest
.

Who are some of Alexion Pharmaceuticals' key competitors?

What other stocks do shareholders of Alexion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alexion Pharmaceuticals investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Alibaba Group (BABA), Netflix (NFLX), Micron Technology (MU), AbbVie (ABBV), Tesla (TSLA), Broadcom (AVGO), The Walt Disney (DIS) and Visa (V).

Who are Alexion Pharmaceuticals' key executives?

Alexion Pharmaceuticals' management team includes the following people:
  • Dr. Ludwig N. Hantson, CEO & Director (Age 57, Pay $3.7M)
  • Dr. Aradhana Sarin M.D., Exec. VP & CFO (Age 45, Pay $1.5M)
  • Mr. Brian M. Goff, Exec. VP and Chief Commercial & Global Operations Officer (Age 51, Pay $1.68M)
  • Dr. John J. Orloff, Exec. VP and Head of R&D (Age 63, Pay $1.76M)
  • Mr. Daniel A. Bazarko CPA, Chief Accounting Officer & Sr. VP
  • Mr. Christopher J. Stevo CFA, Head of Investor Relations
  • Ms. Indrani M. Lall Franchini, Exec. VP & Chief Compliance Officer (Age 48)
  • Ms. Ellen V. Chiniara J.D., Esq., Exec. VP, Chief Legal Officer & Corp. Sec. (Age 61)
  • Megan Goulart, Sr. Director of Corp. Communications
  • Becky Lillie, Interim Chief Human Experience Officer

What is Alexion Pharmaceuticals' stock symbol?

Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."

Who are Alexion Pharmaceuticals' major shareholders?

Alexion Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Scharf Investments LLC (0.25%), DNB Asset Management AS (0.13%), Rhenman & Partners Asset Management AB (0.05%), Vigilant Capital Management LLC (0.04%), Pacer Advisors Inc. (0.03%) and Cullinan Associates Inc. (0.02%). Company insiders that own Alexion Pharmaceuticals stock include Aradhana Sarin, Bros Advisors Lp Baker, Daniel Bazarko, Indrani Lall Franchini and Tanisha Carino.
View institutional ownership trends for Alexion Pharmaceuticals
.

Which institutional investors are selling Alexion Pharmaceuticals stock?

ALXN stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Pendal Group Limited, Pacer Advisors Inc., Scharf Investments LLC, XR Securities LLC, State of Alaska Department of Revenue, Crossmark Global Holdings Inc., and Arden Trust Co. Company insiders that have sold Alexion Pharmaceuticals company stock in the last year include Daniel Bazarko, and Tanisha Carino.
View insider buying and selling activity for Alexion Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Alexion Pharmaceuticals stock?

ALXN stock was purchased by a variety of institutional investors in the last quarter, including DNB Asset Management AS, Guild Investment Management Inc., Exchange Traded Concepts LLC, Louisiana State Employees Retirement System, IFM Investors Pty Ltd, CHURCHILL MANAGEMENT Corp, 6 Meridian, and JustInvest LLC.
View insider buying and selling activity for Alexion Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Alexion Pharmaceuticals?

Shares of ALXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Alexion Pharmaceuticals' stock price today?

One share of ALXN stock can currently be purchased for approximately $157.86.

How big of a company is Alexion Pharmaceuticals?

Alexion Pharmaceuticals has a market capitalization of $34.55 billion and generates $4.99 billion in revenue each year. The biopharmaceutical company earns $2.40 billion in net income (profit) each year or $9.74 on an earnings per share basis. Alexion Pharmaceuticals employs 3,082 workers across the globe.

What is Alexion Pharmaceuticals' official website?

The official website for Alexion Pharmaceuticals is www.alexion.com.

How can I contact Alexion Pharmaceuticals?

Alexion Pharmaceuticals' mailing address is 121 SEAPORT BOULEVARD, BOSTON MA, 02210. The biopharmaceutical company can be reached via phone at 475-230-2596 or via email at [email protected]

This page was last updated on 1/22/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.